מדינה: ניו זילנד
שפה: אנגלית
מקור: Medsafe (Medicines Safety Authority)
Cefuroxime sodium 1578mg equivalent to cefuroxime 1500 mg;
Teva Pharma (New Zealand) Limited
Cefuroxime sodium 1578 mg (equivalent to cefuroxime 1500 mg)
1.5 g
Powder for injection
Active: Cefuroxime sodium 1578mg equivalent to cefuroxime 1500 mg
Prescription
ACS Dobfar SpA
Cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of Gram-positive and Gram-Negative organisms. It is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. Susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. Indications include:
Package - Contents - Shelf Life: Vial, Glass, uncoloured type III vial with bromobutyl type I rubber stopper - 10 dose units - 24 months from date of manufacture stored at or below 25°C protect from light 24 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) protect from light
2014-02-24
Version 1.0 1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME CEFUROXIME ACTAVIS (750 mg, 1.5 g, powder for injection/infusion) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION CEFUROXIME ACTAVIS vials contain 750 mg, or 1.5 g of cefuroxime (as cefuroxime sodium) powder for injection or infusion. 3. PHARMACEUTICAL FORM Powder for injection/ infusion. Cefuroxime is a white to or almost white powder which is produces an off-white suspension for intramuscular use or a yellow solution of intravenous administration after reconstitution with water. Variations in the intensity of this colour do not indicate any change in either the efficacy or safety of the product. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most β-lactamases and is active against a wide range of Gram-positive and Gram-negative organisms. It is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. Susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available (see PHARMACEUTICAL PARTICULARS and PHARMACODYNAMIC PROPERTIES ). Indications include: • Respiratory tract infections for example, acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. • Ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. • Urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. • Soft-tissue infections for example, cellulitis, erysipelas and wound infections. • Bone and joint infections for example, osteomyelitis and septic arthritis. • Obstetric and gynaecological infections, pelvic inflammatory diseases. • Gonorrhoea particularly when penicillin is unsuitable. • Other infections including septicaemia, meningitis and peritonitis. • Prophylaxis against infection in abdominal, קרא את המסמך השלם